Radioligand Therapy / Targeted Radiopharmaceuticals
What are Radioligand Therapy and Targeted Radiopharmaceuticals
Radioligand therapy, also called targeted radiopharmaceutical therapy, is a cancer treatment that couples a tumour-targeting molecule, such as a peptide or antibody fragment, with a therapeutic radioisotope. The targeting molecule binds selectively to receptors on tumour cells, delivering ionising radiation to the cancer while limiting exposure to healthy tissue. Related diagnostic tracers using the same targeting molecules support patient selection and monitoring. Applications focus on oncology, including prostate and neuroendocrine cancers.
What can we do for you
We can analyse the most important global, national and regional trends for you, as well as identify the most important players and trace their development in detail. To do this, we can also break up the technology into sub-technologies.
We can also combine this technology with any other technology to identify interfaces and overlaps, because this is where the hotspots of future technologies are created. In particular, the digital transformation becomes visible in this way, because digital technologies unfold their effects primarily in interaction with other technologies. Contact us.
Ratings and Rankings
Are you interested in the best or most dynamic companies in this technology? Are you looking for the market leaders or the small innovative companies? Global or limited to certain countries or regions? We offer structured rankings with an innovative rating approach. We can provide you with the data in the shortest possible time.
More information about the indicators and the analysis approach:
